

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

2025 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The following is the third quarterly report of Hangzhou Tigermед Consulting Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) for the financial year 2025. This announcement and the accompanying financial statements are originally prepared in Chinese and published in both English and Chinese. If there is any inconsistency or conflict between the Chinese and English versions, the Chinese version shall prevail.

Shareholders of the Company and public investors should note that the accompanying financial statements were prepared in accordance with the China Accounting Standards for Business Enterprises and have not been audited.

By order of the Board
Hangzhou Tigermед Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, October 28, 2025

As at the date of this announcement, the executive directors of the Company are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Mr. Wen Zengyu; the independent non-executive directors of the Company are Mr. Liu Kai Yu Kenneth, Mr. Yuan Huagang and Ms. Liu Yuwen.

HANGZHOU TIGERMED CONSULTING CO., LTD.

2025 THIRD QUARTERLY REPORT

The Company and all members of the Board of Directors warrant that the information disclosed is true, accurate and complete and there is no false representation, misleading statement or material omission.

IMPORTANT NOTICE:

1. The Board of Directors, Board of Supervisors, Directors, Supervisors and senior management warrant that the contents of the quarterly report are true, accurate and complete and there is no false representation, misleading statement or material omission, and take legal responsibilities jointly and severally.
2. The head of the Company, person-in-charge of accounting affairs and head of accounting department (accounting supervisor) warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.
3. Whether the third-quarter financial and accounting report is audited

☐ Yes ☒ No

I. KEY FINANCIAL DATA

(I) Major accounting data and financial indicators

Whether retrospective adjustments or restatements would be made by the Company to the accounting data for prior years

☐ Yes ☒ No

	Reporting Period	Change	Amount from the beginning of the year to the end of the Reporting Period	Change
Revenue (RMB)	1,775,423,981.12	3.86%	5,025,868,260.75	-0.82%
Net profit attributable to shareholders of the listed company (RMB)	637,097,023.97	98.73%	1,020,434,157.81	25.45%
Net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss (RMB)	115,190,184.44	-54.25%	325,942,579.27	-63.46%
Net cash flows from operating activities (RMB)	–	–	739,557,629.57	27.78%
Basic earnings per share (RMB/share)	0.74	100.00%	1.19	26.60%
Diluted earnings per share (RMB/share)	0.74	100.00%	1.19	26.60%
Weighted average return on net assets	3.03%	1.50%	4.89%	1.04%

	End of the Reporting Period	End of prior year	Change
Total assets (RMB)	28,784,251,786.89	28,671,015,787.16	0.39%
Owners' equity attributable to shareholders of the listed company (RMB)	21,176,338,660.50	20,670,653,449.72	2.45%

Note: The Reporting Period shall mean a period of three months from the beginning of this third quarter to the end of this third quarter, the same below.

(II) Items and amounts of extraordinary gain or loss☒ Applicable ☐ Not applicable*Unit: RMB*

Item	Amount for the Reporting Period	Amount from the beginning of the year to the end of the Reporting Period	Remarks
Gain or loss from disposal of non-current assets (including those already written off in the provision for asset impairment)	4,597,364.40	5,223,121.86	Mainly due to the disposal of long-term assets such as fixed assets by the Company during the Reporting Period.
Government grants (except for government grants which are closely related to the ordinary business scope of the Company and entitled in defined standard in conformity with the provisions of policies of the State and that have a sustained impact on the Company's profit or loss) included in the profit or loss for the period	4,943,323.53	24,305,032.44	Mainly due to the government grants received by the Company during the Reporting Period.
Profit or loss arising from changes in fair value of financial assets and financial liabilities held by non-financial companies and profit or loss arising from the disposal of financial assets and financial liabilities (except for those related to effective hedging businesses under ordinary business scope of the Company)	556,686,144.21	653,453,913.55	Mainly due to the investment income recognized from the holding and disposal of other non-current financial assets and gains from changes in fair value of other non-current financial assets of the Company during the Reporting Period.

Item	Amount for the Reporting Period	Amount from the beginning of the year to the end of the Reporting Period	Remarks
Gain or loss from investments on trust or asset management	17,086,916.55	58,769,540.21	Mainly due to the income from wealth management products of the Company during the Reporting Period.
Gain arising from the excess of the fair value of the identifiable net assets of investees on the acquisition date over the investment cost in the Company's subsidiaries, associates and joint ventures	44,973,322.00	44,973,322.00	
Other non-operating income and expenses apart from the above items	-4,664,211.00	-6,239,236.25	
Less: Effect of income tax	23,340,806.51	40,289,713.25	
Effect of minority interests (after tax)	78,375,213.65	45,704,402.02	
Total	521,906,839.53	694,491,578.54	-

Details of other profit or loss items meeting the definition of extraordinary gain or loss:

☐ Applicable ☒ Not applicable

There was no other profit or loss items that met the definition of extraordinary gain or loss.

Explanation on extraordinary gain or loss items defined as recurring gain or loss items as illustrated in the Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No. 1 – Extraordinary Gain or Loss

☐ Applicable ☒ Not applicable

There was no item of extraordinary gain or loss defined as item of recurring gain or loss as illustrated in the Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No. 1 – Extraordinary Gain or Loss.

(III) Changes in key accounting data and financial indicators and the reasons thereof

☒ Applicable ☐ Not applicable

1. Explanation of anomalies for balance sheet items and the reasons thereof

Item	Closing balance (RMB)	Opening balance (RMB)	Change	Reason(s) for change
Notes receivable	9,679,509.20	6,010,700.41	61.04%	Mainly due to the receipt of bank acceptance notes from customers by the Company during the Reporting Period.
Advances to suppliers	142,175,462.53	101,932,971.27	39.48%	Mainly due to the increase in service prepayments to suppliers by the Company during the Reporting Period.
Other receivables	188,040,915.78	89,030,886.84	111.21%	Mainly due to the amounts receivable from the disposal of financial assets by the Company during the Reporting Period.
Inventories	43,942,939.85	31,956,085.52	37.51%	Mainly due to the Company's procurement of materials for experimental purposes during the Reporting Period.
Other non-current assets	2,193,996,550.10	3,245,047,038.72	-32.39%	Mainly due to the redemption of the Company's certificate of deposit during the Reporting Period.
Short-term borrowings	601,815,467.81	1,912,017,204.22	-68.52%	Mainly due to the repayment of short-term borrowings from banks by the Company during the Reporting Period.

Item	Closing balance (RMB)	Opening balance (RMB)	Change	Reason(s) for change
Accounts payable	337,930,501.50	257,287,412.33	31.34%	Mainly due to the increase in purchases from suppliers by the Company during the Reporting Period.
Other paybles	248,763,935.30	76,840,278.73	223.74%	Mainly due to the increase in equity subscription payments by the Company during the Reporting Period.
Contract liabilities	1,103,392,114.97	790,737,308.84	39.54%	Mainly due to the increase in advance payments received by the Company for new orders during the Reporting Period.
Other current liabilities	35,282,719.06	23,223,162.38	51.93%	Mainly due to the presentation of tax amount arising from the increase in the Company's contract liabilities during the Reporting Period.
Long-term borrowings	526,629,225.57	323,649,635.25	62.72%	Mainly due to the increase in long-term borrowings of the Company during the Reporting Period.
Treasury shares	300,069,890.00	191,146,104.89	56.98%	Mainly due to the repurchase of treasury shares by the Company during the Reporting Period.

2. Explanation of anomalies for income statement items and the reasons thereof

Item	Amount from the beginning of the year to the end of the Reporting Period (RMB)	Amount in the same period of prior year (RMB)	Change	Reason(s) for change
Finance expenses	76,159,524.04	31,371,079.58	142.77%	Mainly due to the decrease in the Company's interest income and the increase in foreign exchange losses during the Reporting Period.
Investment income	440,220,795.12	109,158,171.38	303.29%	Mainly due to the increase in gains from investments in associates held, the increase in gains arising from the excess of fair value of the investee's identifiable net assets on the acquisition date over the investment cost in subsidiaries, and the increase in investment income from the disposal of other non-current financial assets during the Reporting Period.
Gain from fair value changes	323,191,353.26	-34,411,947.15	Not applicable	Mainly due to the increase in gains from changes in fair value of other non-current financial assets of the Company during the Reporting Period.
Credit impairment loss	-26,908,313.51	-44,439,217.18	-39.45%	Mainly due to the decrease in bad debt provision for accounts receivable and other receivables made by the Company during the Reporting Period.

Item	Amount from the beginning of the year to the end of the Reporting Period (RMB)	Amount in the same period of prior year (RMB)	Change	Reason(s) for change
Asset impairment loss	-5,401,777.73	-10,657,299.51	-49.31%	Mainly due to the decrease in bad debt provision for contract assets made by the Company during the Reporting Period.
Gain on disposal of assets	5,223,121.86	2,674,931.25	95.26%	Mainly due to the increase in the disposal of long-term assets by the Company during the Reporting Period.
Non-operating income	809,111.08	5,337,204.28	-84.84%	Mainly due to the decrease in government grants received by the Company during the Reporting Period.
Non-operating expenses	7,037,847.33	3,268,133.42	115.35%	Mainly due to the increase in expenses of donations by the Company during the Reporting Period.

3. *Explanation of anomalies for cash flow statement items and the reasons thereof*

Item	Amount from the beginning of the year to the end of the Reporting Period (RMB)	Amount in the same period of prior year (RMB)	Change	Reason(s) for change
Net cash flows from investing activities	493,706,798.02	-5,723,116,899.53	Not applicable	Mainly due to the redemption of the Company's certificate of deposit during the Reporting Period.
Net cash flows from financing activities	-1,684,788,363.95	-272,001,685.95	519.40%	Mainly due to the decrease in net cash inflow from borrowings less cash outflow for debt repayments during the Reporting Period.

II. SHAREHOLDERS' INFORMATION

(I) Total number of ordinary shareholders and the number of preferred shareholders with voting rights restored and the shareholding of top ten shareholders

Unit: share

Total number of ordinary shareholders as at the end of the Reporting Period	48,448	Total number of preferred shareholders with voting rights restored as at the end of the Reporting Period (if any)	0
---	--------	---	---

Shareholding of top 10 shareholders (excluding lending shares through shares lending and refinancing)

Name of shareholder	Nature of shareholder	Shareholding percentage	Number of shares held	Number of	Situation of pledged, marked or	
				shares held	frozen shares	
				subject to	Share status	Quantity
Ye Xiaoping	Domestic natural person	20.58%	177,239,541	132,929,656	Not applicable	0
HKSCC NOMINEES LIMITED	Overseas legal person	14.30%	123,119,129	0	Not applicable	0
Cao Xiaochun	Domestic natural person	5.96%	51,314,174	38,746,330	Pledged	20,000,000
Hong Kong Securities Clearing Company Limited	Overseas legal person	5.62%	48,362,477	0	Not applicable	0
Industrial and Commercial Bank of China Limited – China-Europe Medical and Health Hybrid Securities Investment Fund	Others	3.35%	28,851,689	0	Not applicable	0
Bank of China Limited – Huabao CSI Medical Trading Open-End Index Securities Investment Fund	Others	1.69%	14,567,950	0	Not applicable	0
National Social Security Fund – Portfolio 601	Others	1.33%	11,453,550	0	Not applicable	0
Industrial and Commercial Bank of China Limited – E Fund GEM Trading Open-End Index Securities Investment Fund	Others	1.31%	11,258,550	0	Not applicable	0

Shareholding of top 10 shareholders (excluding lending shares through shares lending and refinancing)

Name of shareholder	Nature of shareholder	Shareholding percentage	Number of shares held	Number of shares held	Situation of pledged, marked or frozen shares	Quantity
				subject to selling restrictions	Share status	
Shi Xiaoli	Domestic natural person	1.13%	9,702,780	0	Pledged	1,496,949
Industrial and Commercial Bank of China Limited – Huatai-PineBridge CSI 300 Trading Open-End Index Securities Investment Fund	Others	1.02%	8,777,866	0	Not applicable	0

Shareholding of top 10 shareholders not subject to selling restrictions (excluding lending shares through shares lending and refinancing and shares subject to lock-up for senior management)

Name of shareholder	Number of shares held not subject to selling restrictions	Class and number of shares		Quantity
		Class of shares		
HKSCC NOMINEES LIMITED	123,119,129	Overseas listed foreign shares		123,119,129
Hong Kong Securities Clearing Company Limited	48,362,477	Renminbi ordinary shares		48,362,477
Ye Xiaoping	44,309,885	Renminbi ordinary shares		44,309,885
Industrial and Commercial Bank of China Limited – China-Europe Medical and Health Hybrid Securities Investment Fund	28,851,689	Renminbi ordinary shares		28,851,689
Bank of China Limited – Huabao CSI Medical Trading Open-End Index Securities Investment Fund	14,567,950	Renminbi ordinary shares		14,567,950
Cao Xiaochun	12,567,844	Renminbi ordinary shares		12,567,844
National Social Security Fund Portfolio 601	11,453,550	Renminbi ordinary shares		11,453,550
Industrial and Commercial Bank of China Limited – E Fund GEM Trading Open-End Index Securities Investment Fund	11,258,550	Renminbi ordinary shares		11,258,550

Shareholding of top 10 shareholders not subject to selling restrictions (excluding lending shares through shares lending and refinancing and shares subject to lock-up for senior management)

Name of shareholder	Number of shares held not subject to selling restrictions	Class and number of shares	
		Class of shares	Quantity
Shi Xiaoli	9,702,780	Renminbi ordinary shares	9,702,780
Industrial and Commercial Bank of China Limited – Huatai-PineBridge CSI 300 Trading Open-End Index Securities Investment Fund	8,777,866	Renminbi ordinary shares	8,777,866

Explanation of the shareholders above who are connected or acting in concert	Ye Xiaoping and Cao Xiaochun signed the Acting-in-Concert Agreement, pursuant to which the two are persons acting in concert and the de facto controllers of the Company.
--	---

Description of top 10 shareholders participating in the margin trading business (if any)	Nil
--	-----

Shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of outstanding shares not subject to selling restrictions participating in lending shares through shares lending and refinancing business

☐ Applicable ☒ Not applicable

Changes in the top 10 shareholders and the top 10 shareholders of outstanding shares not subject to selling restrictions compared with the previous period due to lending/returning shares through shares lending and refinancing

☐ Applicable ☒ Not applicable

(II) Total number of preferred shareholders of the Company and the shareholding of top 10 preferred shareholders

☐ Applicable ☒ Not applicable

(III) Changes in restricted shares

☒ Applicable ☐ Not applicable

Unit: share

Name of shareholder	Number of restricted shares at the beginning of the period	Number of restricted shares unlocked during the period	Number of restricted shares increased during the period	Number of restricted shares at the end of the period	Reasons for the restriction	Proposed date of unlocking the restricted shares
Ye Xiaoping	132,929,656	0	0	132,929,656	Lock-up for senior management	25% of the shares subject to lockup for senior management to be unlocked annually
Cao Xiaochun	38,746,330	0	0	38,746,330	Lock-up for senior management	25% of the shares subject to lockup for senior management to be unlocked annually
Li Xiaori	11,058	0	0	11,058	Lock-up for senior management	25% of the shares subject to lockup for senior management to be unlocked annually
Total	171,687,044	0	0	171,687,044	-	-

III. OTHER SIGNIFICANT EVENTS

☒ Applicable ☐ Not applicable

On July 17, 2025, the Company convened the seventeenth meeting of the fifth session of the Board of Directors to consider and approve the Resolution on the Disposal of Equity Interest in an Investee Company (《關於出售參股公司股權的議案》), pursuant to which LaNova Medicines (禮新醫藥科技(上海)有限公司) intends to transfer 95.09% of its equity interests to Chia Tai Pharmaceutical Investment (Beijing) Group Co., Ltd. (正大製藥投資(北京)集團有限公司). As a shareholder of LaNova Medicines, the Company, after comprehensively analyzing the innovative drug market as well as the core technologies and operational status of the target company, intends to approve the disposal, cooperate with it in the transfer of the entire equity interest directly held by Hangzhou Tigermed Equity Investment Partnership (Limited Partnership) (杭州泰格股權投資合夥企業(有限合夥)) in LaNova Medicines to the purchaser for a consideration of approximately US\$34.11 million, and sign documents relating to such transaction. For details, please refer to the Company's relevant announcement published on cninfo.com on July 18, 2025.

IV. QUARTERLY FINANCIAL STATEMENTS

(I) FINANCIAL STATEMENTS

1. Consolidated balance sheet

Prepared by: Hangzhou Tigermed Consulting Co., Ltd.

September 30, 2025

Unit: RMB

Item	Closing balance	Opening balance
Current assets:		
Cash at bank and on hand	1,648,149,745.63	2,055,344,830.04
Settlement reserve		
Placements with banks and other financial institutions		
Financial assets held for trading	58,000,000.00	74,852,975.16
Derivative financial assets		
Notes receivable	9,679,509.20	6,010,700.41
Accounts receivable	1,427,166,648.66	1,359,758,181.20
Accounts receivable financing		
Advances to suppliers	142,175,462.53	101,932,971.27
Premium receivables		
Amounts due from reinsurers		
Reinsurance contract reserve receivable		
Other receivables	188,040,915.78	89,030,886.84
Including: Interests receivable	2,447,188.11	
Dividends receivable		
Financial assets purchased under agreements to resell		
Inventories	43,942,939.85	31,956,085.52
Including: Data resources		
Contract assets	2,779,362,851.14	2,504,689,617.50
Assets classified as held-for-sale		
Non-current assets due within one year		
Other current assets	54,082,735.38	76,108,977.92
Total current assets	6,350,600,808.17	6,299,685,225.86

Item	Closing balance	Opening balance
Non-current assets:		
Loans and advances to customers		
Bond investments		
Other bond investments		
Long-term receivables	2,613,000.00	
Long-term equity investments	4,092,975,746.66	3,424,603,314.72
Other equity instruments investment	6,438,659.47	8,090,146.65
Other non-current financial assets	10,367,817,610.73	10,105,905,487.26
Investment properties	16,124,831.72	
Fixed assets	741,253,186.79	778,498,376.24
Construction in progress	478,389,559.38	420,535,374.37
Productive biological assets		
Oil and gas assets		
Rights-of-use assets	414,940,010.49	487,230,305.93
Intangible assets	282,092,285.99	336,876,524.01
Including: Data resources		
Development disbursements		
Including: Data resources		
Goodwill	3,512,193,560.02	3,227,762,493.75
Long-term deferred expenses	197,940,426.67	210,094,767.04
Deferred tax assets	126,875,550.70	126,686,732.61
Other non-current assets	2,193,996,550.10	3,245,047,038.72
Total non-current assets	22,433,650,978.72	22,371,330,561.30
Total assets	28,784,251,786.89	28,671,015,787.16

Item	Closing balance	Opening balance
Current liabilities:		
Short-term borrowings	601,815,467.81	1,912,017,204.22
Due to central banks		
Placements from banks and other financial institutions		
Financial liabilities held for trading		
Derivative financial liabilities		
Notes payable	5,889,386.07	
Accounts payable	337,930,501.50	257,287,412.33
Advanced receipts		
Contract liabilities	1,103,392,114.97	790,737,308.84
Financial assets sold under agreement to repurchase		
Customer deposits and placements from other financial institutions		
Customer brokerage deposits		
Securities underwriting brokerage deposits		
Employee benefits payable	255,819,604.16	243,974,190.43
Tax payable	139,601,225.19	159,172,131.01
Other payables	248,763,935.30	76,840,278.73
Including: Interests payable		5,310,915.46
Dividends payable	472,636.68	2,609,775.37
Fees and commissions payable		
Amounts due to reinsurer		
Liabilities classified as held-for-sale		
Non-current liabilities due within one year	209,358,058.98	198,600,777.18
Other current liabilities	35,282,719.06	23,223,162.38
Total current liabilities	2,937,853,013.04	3,661,852,465.12

Item	Closing balance	Opening balance
Non-current liabilities:		
Reserve of insurance contract		
Long-term borrowings	526,629,225.57	323,649,635.25
Bonds payable	51,041,151.09	
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	357,226,050.15	399,316,716.16
Long-term payables	10,000,000.00	
Long-term employee benefits payable	2,731,588.57	2,784,565.42
Provisions		
Deferred revenue	15,491,664.47	17,136,295.72
Deferred tax liabilities	175,249,630.09	201,796,922.90
Other non-current liabilities	436,160.59	
Total non-current liabilities	1,138,805,470.53	944,684,135.45
Total liabilities	4,076,658,483.57	4,606,536,600.57
Owners' equity:		
Share capital	861,026,050.00	864,948,570.00
Other equity instruments		
Including: Preferred shares		
Perpetual bonds		
Capital surplus	10,618,447,999.46	10,772,578,438.11
Less: Treasury shares	300,069,890.00	191,146,104.89
Other comprehensive income	107,866,176.97	99,095,699.24
Special reserve		
Surplus reserve	436,529,393.76	436,529,393.76
General risk provision		
Retained earnings	9,452,538,930.31	8,688,647,453.50
Total equity attributable to owners of the parent	21,176,338,660.50	20,670,653,449.72
Non-controlling interests	3,531,254,642.82	3,393,825,736.87
Total owners' equity	24,707,593,303.32	24,064,479,186.59
Total liabilities and owners' equity	28,784,251,786.89	28,671,015,787.16

Legal representative: **Cao Xiaochun**
 Person-in-charge of accounting affairs: **Yang Chengcheng**
 Head of accounting department: **Xia Jiangmei**

2. Consolidated income statement from the beginning of the year to the end of the Reporting Period

Unit: RMB

Item	Amount for the Reporting Period	Amount for the prior period
I. Total revenue	5,025,868,260.75	5,067,615,359.89
Including: Operating income	5,025,868,260.75	5,067,615,359.89
Interest income		
Premium earned		
Fees and commission income		
II. Total cost of sales	4,559,527,495.20	4,026,550,519.06
Including: Operating cost	3,560,252,024.84	3,097,333,423.23
Interest expenses		
Fees and commission expenses		
Cash surrender value		
Claim settlement expenses, net		
Net provision of insurance contract liabilities		
Policy dividend expense		
Reinsurance expenses		
Business tax and surcharge	25,585,746.05	22,385,614.14
Selling expenses	175,449,787.82	144,935,323.39
General and administrative expenses	530,840,458.53	558,426,318.44
Research and development expenses	191,239,953.92	172,098,760.28
Finance expenses	76,159,524.04	31,371,079.58
Including: Interest expenses		
Interest income		
Add: Other income	26,343,546.96	21,606,421.27
Investment income (losses are expressed by "-")	440,220,795.12	109,158,171.38
Including: Income from investment in associates and joint ventures		
Gain on de-recognition of financial assets at amortized cost		
Foreign exchange gain (losses are expressed by "-")		
Net exposure hedging gain (losses are expressed by "-")		
Gain from fair value change (losses are expressed by "-")	323,191,353.26	-34,411,947.15
Credit impairment loss (losses are expressed by "-")	-26,908,313.51	-44,439,217.18
Asset impairment loss (losses are expressed by "-")	-5,401,777.73	-10,657,299.51
Gain on disposal of assets (losses are expressed by "-")	5,223,121.86	2,674,931.25

Item	Amount for the Reporting Period	Amount for the prior period
III. Operating profit (losses are expressed by “-”)	1,229,009,491.51	1,084,995,900.89
Add: Non-operating income	809,111.08	5,337,204.28
Less: Non-operating expenses	7,037,847.33	3,268,133.42
IV. Total profits (total losses are expressed by “-”)	1,222,780,755.26	1,087,064,971.75
Less: Income tax expenses	131,099,588.80	183,929,494.79
V. Net profits (net losses are expressed by “-”)	1,091,681,166.46	903,135,476.96
(I) Classified by continuing operations		
1. Net profits from continuing operations (net losses are expressed by “-”)	1,091,681,166.46	903,135,476.96
2. Net profits from discontinued operations (net losses are expressed by “-”)		
(II) Classified by ownership of equity		
1. Net profits attributable to shareholders of the parent (net losses are expressed by “-”)	1,020,434,157.81	813,428,915.46
2. Non-controlling gain or loss (net losses are expressed by “-”)	71,247,008.65	89,706,561.50
VI. Other comprehensive income, net of tax	9,646,423.79	-50,709,884.36
Other comprehensive income attributable to owners of the parent, net of tax	8,770,477.73	-26,157,226.69
(I) Items that will not be reclassified subsequently to profit or loss	444,801.15	-1,725,389.26
1. Changes arising from re-measurement of defined benefit obligation		
2. Other comprehensive income accounted for using the equity method, which will not be reclassified subsequently to profit or loss		
3. Change in fair value of other equity instruments investment	444,801.15	-1,725,389.26
4. Change in fair value of credit risk of the Company		
5. Others		

Item	Amount for the Reporting Period	Amount for the prior period
(II) Items that may be reclassified to profit or loss	8,325,676.58	-24,431,837.43
1. Other comprehensive income accounted for using the equity method, which may be reclassified subsequently to profit or loss		
2. Change in fair value of other bond investments		
3. Other comprehensive income due to reclassification of financial assets		
4. Credit impairment loss on other bond investments		
5. Cash flow hedge reserve		
6. Currency translation difference	8,325,676.58	-24,431,837.43
7. Others		
Other comprehensive income attributable to noncontrolling interests, net of tax	875,946.06	-24,552,657.67
VII. Total comprehensive income	1,101,327,590.25	852,425,592.60
(I) Total comprehensive income attributable to owners of the parent	1,029,204,635.54	787,271,688.77
(II) Total comprehensive income attributable to noncontrolling interests	72,122,954.71	65,153,903.83
VIII. Earnings per share:		
(I) Basic earnings per share	1.19	0.94
(II) Diluted earnings per share	1.19	0.94

For the business combination under common control in the Reporting Period, the net profit realized by the acquiree before the combination was nil, and the net profit realized by the acquiree in the prior period was nil.

<i>Legal representative:</i>	<i>Person-in-charge of accounting affairs:</i>	<i>Head of accounting department:</i>
Cao Xiaochun	Yang Chengcheng	Xia Jiangmei

3. Consolidated cash flow statement from the beginning of the year to the end of the Reporting Period

Unit: RMB

Item	Amount for the Reporting Period	Amount for the prior period
I. Cash flows from operating activities:		
Cash received from sale of goods or rendering of services	5,317,979,333.00	4,856,126,172.22
Net increase in customer deposits and placements from other banks		
Net increase in due to central bank		
Net increase in borrowings from other financial institutions		
Cash from premiums on original insurance contracts		
Cash received from reinsurance business, net		
Net increase in insured's deposits and investments		
Cash received from interest, fees and commissions		
Net increase in placements from banks and other financial institutions		
Net increase of funds in repurchase business		
Net cash received from customer brokerage		
Tax refunds	14,560,502.32	2,149,719.16
Cash receipts related to other operating activities	81,749,437.45	135,443,635.26
Sub-total of cash inflows from operating activities	5,414,289,272.77	4,993,719,526.64
Cash paid for goods and services	1,592,666,205.03	1,378,495,566.27
Net increase in loans and advances to customers		
Net increase in deposits with central bank and other banks		
Cash paid for claim settlements on original insurance contracts		
Net increase in placements with banks and other financial institutions		
Cash paid for interest, fees and commissions		
Cash paid for policy dividends		
Cash paid to and for employee benefits	2,363,815,844.10	2,298,577,074.56
Payments of all types of taxes	320,605,174.81	436,973,562.51
Cash payments related to other operating activities	397,644,419.26	300,903,713.35
Sub-total of cash outflows from operating activities	4,674,731,643.20	4,414,949,916.69
Net cash flows from operating activities	739,557,629.57	578,769,609.95

Item	Amount for the Reporting Period	Amount for the prior period
II. Cash flows from investing activities:		
Cash received from sale of investments	1,777,634,145.31	619,025,446.77
Cash receipts from returns on investments	165,736,772.10	33,510,950.69
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	2,139,573.13	188,383.44
Net cash received from disposal of subsidiaries and other business units		
Cash receipts related to other investing activities	17,128,630.27	14,687,103.15
Sub-total of cash inflows from investing activities	1,962,639,120.81	667,411,884.05
Cash paid to acquire fixed assets, intangible assets and other long-term assets	173,581,867.91	278,061,741.81
Cash paid for investments	1,138,161,366.31	6,091,185,860.30
Net increase in pledged loans		
Net cash paid for acquisition of subsidiaries and other business units	115,646,821.75	20,964,321.47
Cash payments related to other investing activities	41,542,266.82	316,860.00
Sub-total of cash outflows from investing activities	1,468,932,322.79	6,390,528,783.58
Net cash flows from investing activities	493,706,798.02	-5,723,116,899.53
III. Cash flows from financing activities:		
Cash receipts from capital contributions	162,098,000.00	61,900,000.00
Including: Cash receipts from capital contributions from non- controlling interests of subsidiaries		
Cash received from borrowings	1,044,986,871.59	2,843,516,597.92
Cash receipts related to other financing activities	61,200,000.00	107,255,379.29
Sub-total of cash inflows from financing activities	1,268,284,871.59	3,012,671,977.21
Cash repayments for debts	2,170,230,969.65	2,035,406,823.68
Cash payments for distribution of dividends, profits or interest expenses	341,108,089.30	608,854,337.03
Including: Dividends and profits paid to non-controlling interests by subsidiaries		
Cash payments related to other financing activities	441,734,176.59	640,412,502.45
Sub-total of cash outflows from financing activities	2,953,073,235.54	3,284,673,663.16
Net cash flows from financing activities	-1,684,788,363.95	-272,001,685.95
IV. Effect of change in foreign exchange rates on cash and cash equivalents	2,935,487.08	-21,705,538.24
V. Net increase in cash and cash equivalents	-448,588,449.28	-5,438,054,513.77
Add: Cash and cash equivalents at the beginning of the period	2,048,493,852.84	7,399,941,369.85
VI. Cash and cash equivalents at the end of the period	1,599,905,403.56	1,961,886,856.08

(II) Particulars in relation to adjustments made to the financial statements as at the beginning of the year of the initial adoption of new accounting standards since 2025

☐ Applicable ☒ Not applicable

(III) AUDIT REPORT

Whether the third-quarter financial and accounting report is audited

☐ Yes ☒ No

The third-quarter financial and accounting report of the Company is unaudited.

The Board of Directors of Hangzhou Tigermed Consulting Co., Ltd.